We have devised a strategy (called recombinase-mediated genomic replacement, RMGR) to allow the replacement of large segments (>100 kb) of the mouse genome with the equivalent human syntenic region. The technique involves modifying a mouse ES cell chromosome and a human BAC by inserting heterotypic lox sites to flank the proposed exchange interval and then using Cre recombinase to achieve segmental exchange. We have demonstrated the feasibility of this approach by replacing the mouse a globin regulatory domain with the human syntenic region and generating homozygous mice that produce only human a globin chains. Furthermore, modified ES cells can be used iteratively for functional studies, and here, as an example, we have used RMGR to produce an accurate mouse model of human a thalassemia. RMGR has general applicability and will overcome limitations inherent in current transgenic technology when studying the expression of human genes and modeling human genetic diseases.
SUMMARY
We have devised a strategy (called recombinase-mediated genomic replacement, RMGR) to allow the replacement of large segments (>100 kb) of the mouse genome with the equivalent human syntenic region. The technique involves modifying a mouse ES cell chromosome and a human BAC by inserting heterotypic lox sites to flank the proposed exchange interval and then using Cre recombinase to achieve segmental exchange. We have demonstrated the feasibility of this approach by replacing the mouse a globin regulatory domain with the human syntenic region and generating homozygous mice that produce only human a globin chains. Furthermore, modified ES cells can be used iteratively for functional studies, and here, as an example, we have used RMGR to produce an accurate mouse model of human a thalassemia. RMGR has general applicability and will overcome limitations inherent in current transgenic technology when studying the expression of human genes and modeling human genetic diseases.
INTRODUCTION
Studies of how human genes are normally regulated and the effects of mutations that cause human genetic disease are limited by the availability of appropriate primary cells and tissues and the necessary constraints on experimental interventions. Consequently, over the past 20 years, transgenic mice have become important experimental models to understand how human genes are regulated.
Small transgenes, however, often do not contain all of the cis-acting elements required for fully regulated expression since such sequences may be found tens or even hundreds of kilobases from the gene in question (Kleinjan and van Heyningen, 2005) . Even when large transgenes derived from PACs, BACs or YACs are used, they are frequently rearranged; it is often very difficult to fully analyze their structural integrity and copy number (Peterson et al., 1998) . Furthermore, their expression is often influenced by their position of integration in the genome (Alami et al., 2000; Kaufman et al., 1999) . Making and characterizing directed mutations for structure/function studies is also difficult when using such large molecules. Even when successful, the interpretation of these transgenic experiments is complicated by the fact that the endogenous mouse genes are still present unless bred against mice in which they have been deleted or inactivated by homologous recombination.
A complementary approach is to identify the mouse ortholog and alter this gene or its regulatory elements by homologous recombination using conventional genetargeting methods (Nagy, 2003) . Clearly, mutating a single gene at its normal chromosomal locus avoids many of the problems associated with transgenes (copy number differences, complex mapping problems, position effects), and, in this process, the normal endogenous gene does not remain intact to complicate the analysis. However, there is increasing evidence demonstrating considerable differences in the ways in which orthologous human and mouse genes are normally regulated. In many instances, mutations known to cause disease in human do not mimic the phenotype when introduced into the mouse ortholog (Colledge et al., 1995; Engle et al., 1996; Garrick et al., 2006) . These include the a globin locus, where deletion of the major regulatory element causes a much milder condition in mouse than in human (Anguita et al., 2002) . Therefore, although mouse models have provided many insights into human genetic disease, it is becoming increasingly clear that they are also beset by inherent problems and difficulties in interpretation resulting from differences in basic biological processes that have evolved over the 70 million years of evolution that separate humans and mice.
Clearly, the next step in developing mouse models of human disease is to replace large segments (100-1000s kb) of the mouse genome with the wild-type or mutated syntenic region of the human sequence, thereby including all remote regulatory elements and inserting the human segment as a single copy at a natural chromosomal position for the genes contained within it. A range of chromosome-engineering technologies are now available that, combined in a novel way, could make this feasible (Yu and Bradley, 2001; Copeland et al., 2001; Muyrers et al., 2001; Testa et al., 2003; Valenzuela et al., 2003; Yang and Seed, 2003) , including application of various heterotypic site-specific recombination systems (Cre, FLP, fC31) to achieve efficient exchange of sequence cassettes at targeted chromosomal loci, a process known as recombinase-mediated cassette exchange (RMCE) (Baer and Bode, 2001) .
In this study, we have combined various aspects of these technologies to develop what we believe to be a new, general strategy for replacing large segments of the mouse genome with wild-type or mutated syntenic regions of the human genome. We refer to this process as recombinase-mediated genomic replacement (RMGR). This allows precise, reproducible, genetically selectable genomic replacement on a scale not previously attained and should be generally applicable to large-scale modification of the mouse genome. We have established a ''proof of principle'' for its application in generating ''humanized'' mice by replacing the syntenic region encompassing the mouse a globin regulatory domain (the region containing all cis-acting sequences required for fully regulated expression of the a globin genes) with human BAC-derived sequence in ES cells and subsequently deriving viable mice homozygous for this syntenic substitution producing only human a-globin chains. In addition, we have demonstrated the potential of this approach for making authentic mouse models of human disease by replacing the mouse region with a recombineered human BAC in which the a globin major regulatory element has been deleted from the a globin regulatory domain. This created a model of a thalassemia that faithfully mimics the phenotype of patients with this common human genetic disease.
RESULTS

Genomic Replacement Strategy for Substitution of the a Globin Gene Domain
We set out to exchange an extensive part of the mouse genome with its human equivalent in a region where the consequences could be clearly analyzed. We chose the region encompassing the a globin gene cluster since this has been fully characterized both structurally (Flint et al., 2001; Hughes et al., 2005; Kielman et al., 1996) and functionally (Anguita et al., 2001 (Anguita et al., , 2002 (Anguita et al., , 2004 in both mouse and man. The gene order and transcriptional orientation of the globin genes and other widely expressed genes flanking them in this segment of the genome are highly conserved ( Figure 1) ; a multispecies DNA comparison shows that the region of most conserved synteny extends from the DIST gene (a rhomboid-like gene also known as c16orf8, gene 5 in Figure 1 ) to the q globin gene (Hughes et al., 2005) . This region contains all known multispecies conserved regulatory elements (MCS-Rs), the corresponding erythroid-specific DNase1 hypersensitive sites and well-defined segments of chromatin that become acetylated specifically in erythroid cells (Anguita et al., 2001 (Anguita et al., , 2002 Higgs et al., 1998) . This region is therefore thought to encompass the entire a globin regulatory region (Figure 1) .
In outline, the plan involved insertion of noninteracting (heterospecific) lox recombination sites (loxP and lox511) into positions (in the Dist and q genes, respectively) flanking the a globin regulatory domain in the mouse ES cell chromosome and in the corresponding regions of a BAC (344L6) that spans the entire ($120 kb) human a globin region. In the presence of Cre recombinase, reciprocal exchange of sequence between the BAC and mouse chromosome should occur since only the compatible loxP/loxP and lox511/lox511 sites will recombine (Bethke and Sauer, 1997) and thus result in replacement of the entire mouse regulatory region in the ES cell genome with the corresponding human region (Figure 1) .
We chose the fourth intron of the DIST gene to insert the loxP sites (upstream exchange points) in both mouse (ES cells) and human (BAC) sequences and the second intron of the 3 0 q gene in mouse (ES cells) and the corresponding region of the second intron of the single human q gene (BAC) (Figures 1-3 ) to insert the lox511 sites (downstream exchange points). When recombination is activated, this should result in the exchange of 117 kb of human sequence for the equivalent 85 kb of mouse sequence, creating a hybrid human-mouse DIST gene upstream and a hybrid human-mouse q gene downstream in the recombinant mouse chromosome.
Targeted Modifications of the a Globin Regulatory Domain in Mouse ES Cells
The strategy required the sequential insertion of a loxP site and then a lox511 site (in inverted orientation) into the upstream and downstream positions of the mouse a globin cluster by conventional homologous recombination (Mansour et al., 1988) . The vectors designed to achieve this also integrated genetic markers directly linked to the loxP and lox511 sites to enable selection of the chromosome replacement in the second stage. Positive genetic selection for loxP 3 loxP recombination involved reconstruction of a functional hypoxanthinephosphoribosyltransferase (Hprt) minigene from defective 5 0 and 3 0 components (Smith et al., 1995) , and negative selection for lox511 3 lox511 recombination involved the use of HSV thymidine kinase (tk) genes. E14-TG2a.IV ES cells, and correctly targeted clones were obtained ( Figure 2B ). One of these Dist-targeted clones was used for a second round of homologous recombination to target the q gene using a vector with the PGKpuro/MC1tk/lox511/I-SceI cassette ( Figure 2C ), and several independently targeted clones were obtained. Double Dist-q targeted clones should contain the integrated cassettes either on the same chromosome (in-cis targeting) or on each of the two homologs (in-trans targeting). We distinguished these based on the efficiency of Cre-mediated recombination when a plasmid pBS-loxP/ Hprt -D5 0 /lox511, coelectroporated with a Cre expression plasmid, interacted with the integrated cassettes reconstructing a functional Hprt minigene. Cells with sites incis should result in a higher frequency of recombination relative to those in-trans, as measured by the frequency of HPRT + colonies (see Supplemental Data Section S3, Figure S1 , and Table S1 , available with this article online). On this basis, three from 12 independent cell lines (2/ B-6, 2/H-1, and 2/H-10) were assigned as having incis-targeted Dist and q genes.
Targeted Modifications of the Human a Globin Cluster in a BAC
A human BAC clone, 344L6, covering the interval from 3 kb upstream of the IL-9RP3 pseudogene to 18 kb downstream of the q gene provided the human sequences. This BAC was modified by inserting loxP and lox511 sites (in the equivalent positions and in the same orientations as in the mouse chromosome) using l Red-mediated homologous recombination in the E. coli strain DY380 (Lee et al., 2001 ). The human DIST gene was targeted with the vector containing the I-SceI/loxP/PGK-Tn903hyg/ loxP/Hprt -D5 0 /frt cassette ( Figure 3A) , and the q gene was targeted with the vector containing the lox511/PGKTn903neo/MC1tk/I-SceI cassette ( Figure 3B ). Finally, it was necessary to remove a second, pre-existing, endogenous lox511 site present in the BACe3.6 vector; an additional recombination event was therefore carried out to replace the endogenous lox511 site with a blasticidin selection cassette ( Figure 3C ), which consequently would also permit the detection of any potential random BAC backbone DNA integration in ES cells.
Selection and Characterization of the Genome Replacement Event
The vectors used to target the mouse and human DIST genes (Figures 2A and 3A) inserted the loxP sites and their linked Hprt -D3 0 and Hprt -D5 0 sequences, respectively, in the opposite transcriptional orientation to the Dist gene. This should create a reconstructed Hprt minigene after Cremediated recombination located in the recombinant mouse chromosome. The vectors used to target the mouse and human q genes ( Figures 2C and 3B ) inserted the lox511 sites in the same orientation but opposite to that of the loxP site. The relative order of the lox511 and linked HSV thymidine kinase negative selection marker, MC1tk, should, after Cre-mediated recombination, result in a recombinant mouse chromosome lacking a negative selection marker. This overall arrangement of targeted sequences in the ES cells and the BAC necessary to implement the desired Cre-mediated exchange is illustrated in Figures 4A and  4B . The reciprocal recombinant BAC product (not shown) should remain unintegrated and therefore be lost after cell division. ES cells with the resulting recombinant mouse chromosome will have an HPRT + , ganciclovir-resistant phenotype. Two cell lines, 2/B-6 and 2/H-1, with putative in-cis-targeted events at the Dist and q loci were coelectroporated in an approximate 1:10 molar ratio with the modified BAC and a Cre recombinase expressing plasmid (pCAGGSCre-IRESpuro) (Smith et al., 2002) , and HPRT + cells subsequently selected in medium with hypoxanthine, aminopterin, and thymidine (HAT). HAT-resistant (HAT R )
colonies were obtained at an approximate frequency of 1 3 10 À8 (an average value determined from three independent electroporations). Two independent colonies derived from the 2/B-6 ES cell line and one from the 2/H-1 line were obtained. All three were resistant to ganciclovir, indicating that Cre-mediated exchange had also occurred via the lox511 site at the q gene ( Figures 4A and 4B ). In addition, the cells were sensitive to hygromycin, puromycin, and G418, indicating that the expected loss of these markers had occurred ( Figure 4B ). Sensitivity to blasticidin suggested that there was no random integration of the reciprocal BAC product of the exchange event nor had the BAC DNA integrated by nonhomologous recombination.
The reconstructed Hprt minigene embedded in the Dist gene and now flanked by directly repeated frt sites was subsequently excised by electroporating the FLPeexpressing plasmid pCAGGS-FLPe-IRESpuro (Schaft et al., 2001 ) into the cells. Resistant clones were recovered at a high frequency after selection in media supplemented with 6-thioguanine (6-TG). This final modification resulted in a replacement event in which the only extraneous sequence remaining is an frt site at the Dist end of the interval and a lox511site and I-SceI site at the q end ( Figure 4C ).
To confirm the anticipated Cre and FLPe recombination events had occurred at the exchange end points, genomic DNA from the HAT R and 6-TG R clones was analyzed by extensive Southern blot analysis. Fragments of the predicted sizes ( Figures 4D and 4E [lanes 1 to 6] and Figures S2 and S3) confirmed that the expected mouse-human junction sequences had been created at both ends of the exchange interval. All three of the independent HAT R clones (and their 6-TG-resistant derivative clones) contained the Cre-mediated exchange event.
Generating Mice Containing the Human a Globin Gene Cluster Replacement
The HAT R cell lines with replacements containing the wildtype human a globin gene cluster (2/B-6R1, 2/B-6R2, and 2/H-1R1, all of which retained the Hprt minigene) were used to generate chimeras. All three ES cell lines gave rise to male chimeras that transmitted the recombinant chromosome.
Of the three mouse lines in which the human a globin regulatory domain replaced the mouse domain, one (line 1, derived from 2/B-6R1) was mapped in detail and a second (line 3, derived from 2/H-1R1) in less fine detail. In both lines, the a globin regulatory domain was shown to be intact and structurally normal ( Figure S2 ). Line 2 (derived from 2/B-6R2) showed some anomalous bands, and further investigation (data not shown) demonstrated this line had an internal deletion of the BAC replacement region that encompassed at least some of the gene 7 sequence but did not extend into the sequence of the MPG or z genes. This deletion was subsequently found to be present in the ES cell line and presumably arose during the exchange event. This line was not analyzed further.
When heterozygotes established on a mixed (129/Ola)/ (C57BL/6)/(CBA) genetic background from both lines (1 and 3) were mated, offspring homozygous for the recombinant chromosome were produced but not in the expected 1 in 4 Mendelian ratio (3 homozygotes: 20 heterozygotes: 12 wild-type). Surviving homozygotes developed normally and were fertile, albeit with significant hematological abnormalities (see below). From homozygote 3 heterozygote crosses, 6/16 homozygotes were obtained. Some homozygotes appeared, therefore, to be lost in utero, and of those that were born, 3/9 died in the neonatal period.
Mice from lines 1 and 3 were crossed with a FLPe recombinase germline deleter C57BL/6 strain (unpublished). Analyses of mice carrying the recombinant chromosome and the FLPe transgene confirmed deletion of the Hprt gene as predicted, and these were subsequently intercrossed. Southern blot analysis identified embryos and pups from the intercross that were homozygous for the now modified recombinant chromosome ( Figure S3 ). Two viable homozygotes lacking the Hprt gene were produced and were hematologically indistinguishable from those that retained the Hprt gene, demonstrating that the presence of the Hprt gene and its regulatory elements had no apparent effects on the expression of genes within the a globin region (Table 1B) . After further backcrossing onto a C57BL/6 background (three generations) heterozygotes with the Hprt gene deleted when intercrossed still produced a deficiency of viable homozygous offspring.
In Vivo Analysis of Mice Carrying a Human a Globin Gene Cluster Replacement
To visualize the exchange, splenic lymphocyte metaphases from a heterozygote with the recombinant chromosome (line 1) were hybridized with differentially labeled probes for the mouse and human a globin gene clusters together with a chromosome 11 paint. In each cell, one chromosome 11 carried a human hybridization signal, while its homolog bore a mouse signal, confirming that one of the mouse chromosomes had the human replacement event and that no additional insertions had occurred ( Figure 5) .
Expression of the genes from the region containing the human a globin domain was first checked by hybridization of RNA from the erythroblasts of a homozygous, humanized mouse to an Affymetrix tiled microarray containing all unique sequences in the terminal 300 kb of chromosome 16 (De Gobbi et al., 2006) . The pattern of expression was very similar to that seen from normal human erythroblasts ( Figure 6A ). Using RT-PCR, transcripts from the MPG, PROX, a D , and a A genes were readily detected in peripheral blood and spleen ( Figure 6B ). The low levels of a globin RNA in brain was consistent with blood contamination. A hybrid RNA crossing the DIST gene breakpoint was detected using 5 0 human and 3 0 mouse primers in brain, spleen, and blood from a heterozygote from which the Hprt minigene had been excised. Similarly, we detected the hybrid RNA crossing the breakpoint that lies in the human and mouse q gene ( Figure 6C) .
Expression of human and mouse a globin mRNA was measured in adult peripheral blood samples by both quantitative real-time PCR and by RNase protection assays (RPA). The results (Table 1 and Figures 6D-6F ) were similar for both lines analyzed and by both methods and show that expression from the recombinant chromosome is Figure 6E ) confirms that the normal developmental pattern of globin gene expression is retained. Blood films from the mice carrying one copy of the recombinant chromosome were largely normal in appearance, with a minor increase in anisopoikilocytosis (abnormally shaped cells). No difference was evident between the two lines. Red cells from the homozygotes were more markedly abnormal, with microcytic (small), hypochromic (pale) anisopoikilocytotic cells producing a typical thalassemic picture ( Figure S4 ). Blood counts from an automated counter (ABX Pentra 60) confirmed that in heterozygotes the Hb level, mean cell volume (MCV), and mean cell hemoglobin (MCH) were normal, while the homozygotes had normal Hb levels but a raised reticulocyte count and reduced MCV and MCH values. These values were similar (Table 1) to those from thalassemic mice heterozygous for a targeted deletion (Pá szty et al., 1995) of both a globin structural genes (--/aa).
Deletion of the HS -40 Regulatory Element in the a Globin Gene Cluster
The RMGR strategy was designed to facilitate rapid recursive introduction of mutations into the exchange region by additional rounds of BAC modification using l Red-mediated recombination prior to Cre recombination in ES cells to allow systematic in vivo functional analyses of human regulatory elements. As a proof of principle, l Red-mediated recombination was used to remove a 1.1 kb region containing the HS -40 regulatory site that lies in intron 5 of the C16orf35 (also known as the PROX gene; gene 7 in Figure 1 ) gene ( Figure 3D ) in the triple targeted BAC. The 1.1 kb region was replaced with a PGK/EM7puro selection cassette flanked with direct repeats of the heterospecific frt site F3 (Schlake and Bode, 1994) ; to enable its subsequent excision by FLPe recombinase without intrachromosomal recombination occurring with the frt sites flanking the Hprt minigene. Figures 3D and 3F (lane 5) show the expected change of a HindIII fragment from 4.1 kb to 4.6 kb. The modified BAC was coelectroporated into the recipient 2/B-6 ES cells, in the presence of Cre, and a single HAT-resistant clone, resistant to ganciclovir and puromycin, was recovered, consistent with the anticipated replacement recombination event. Southern blot analysis of this clone, and of independent 6-TG R derivative clones (which were also puromycin sensitive) obtained subsequent to electroporation with the FLPe-expressing plasmid, showed the identical restriction fragment size changes corresponding to the mouse-human junction sequences (Figures 4D and 4E [lanes 7 to 10]) obtained with the original replacement event. The frequency of puromycin-sensitive clones (approximately 50% of total 6-TG R clones) and the identical restriction fragment size change consistently seen in 6-TG R puromycin-sensitive clones across the mouse/ human Dist junction indicated that efficient codeletion of the Hprt and PGK/EM7puro selection cassettes occurred without heterotypic frt 3 frt-F3 recombination events and consequent intrachromosomal rearrangement.
Characterization of Mice Carrying a Human a Globin Gene Cluster Replacement with the HS -40 Deletion
The HAT R cell line containing the human a-globin gene cluster from which HS -40 had been deleted (but retaining the Hprt minigene) also generated a transmitting male chimera. Mapping of this line showed only the expected band sizes.
When these heterozygotes were crossed, homozygotes were phenotypically indistinguishable from littermates at 10.5 days gestation but by genotyping were detectable at normal frequencies. By 11.5 days gestation, homozygotes were identifiable as small, pale, dead embryos that had presumably died from severe anemia.
Expression of the human a globin genes in adult heterozygotes carrying the human cluster from which the major regulatory element (HS -40) had been deleted ( Figure 6E ) was reduced to barely detectable levels (<2%), in keeping with results from human patients in whom this element is missing (Higgs et al., 1998) . In embryos, human RNA levels were again severely reduced, with z not as extremely affected as a ( Figure 6F ).
Red cell morphology was also abnormal in mice carrying the mutated human sequence (D HS -40); hypochromia, microcytosis, and target cells were prevalent as well as marked anisopoikilocytosis ( Figure S4 ). These films were similar to those from thalassemic mice heterozygous for , and a (left panel) was detected in spleen, peripheral blood, and brain samples from a heterozygote from line 1 and in spleen from a D HS -40 heterozygote, using gene-specific primers. Likewise, expression of Mpg, Prox, and a was present in the murine locus (right panel). Low levels of expression of a globin in nonerythroid tissues is due to contamination with small amounts of blood. a targeted deletion (Pá szty et al., 1995) of both a globin structural genes (--/aa). Blood counts showed a reduced Hb level and low MCV and MCH, similar to those from --/aa mice ( Table 1 ). The puromycin selection marker gene, which replaced the HS -40 element, and the Hprt minigene were excised by crossing this line with the FLPe recombinase deleter line. Hematological analyses of two adult mice derived from this cross carrying the now modified, mutated human sequence were indistinguishable from mice in which these selection marker genes had not been excised (Table 1) .
DISCUSSION
Here we have shown that it is possible to precisely replace a large segment of the mouse genome containing multiple loci with the corresponding, syntenic segment of the human genome. Combining a variety of developments in chromosome engineering, RMGR has significantly extended the principles underpinning RMCE to enable extensive tracts (100s to 1000s kb) of mouse genomic DNA to be replaced by the orthologous sequences of other species cloned in BAC libraries. RMGR will therefore be widely applicable and offers several advantages over other approaches to large-scale genome modification. In particular, correct genomic replacement using RMGR is genetically selectable, precise, and reproducible. This reduces the effort of screening and greatly simplifies the characterization of the chromosomal breakpoints. Minimal extraneous DNA remains to affect the functional integrity of the engineered chromosomal region, provided the locations of the recombination sites are chosen carefully. Once correctly targeted, germline transmitting ES cells are established, RMGR allows iterative replacement with mutated BACs for detailed functional dissection of genomic sequences. Although the frequency of replacement is low, it is reproducible. General application may reveal locus-specific and/or BAC-specific variations in efficiency requiring adjustments to the electroporation parameters. The RMGR strategy will be adaptable for application with other (e.g., fC31) (Belteki et al., 2003) site-specific recombination systems to improve the overall efficiency and allow the Cre/lox system to be used to introduce conditional deletions within the human sequence. In its present form, the extent of sequence replacement is limited only by the size of the BAC inserts. Recent approaches to construct mega-BACs (Shen et al., 2005) in E. coli will therefore extend the size range of replacements possible.
By analyzing the well-characterized a globin regulatory domain by RMGR, we could be confident that the structurally intact segment contains all known cis-acting elements, at a single copy in a chromosomal position that is appropriate for globin gene expression. Furthermore, by carefully examining gene expression in erythropoiesis and evaluating the resulting, sensitive red cell phenotype, we could accurately assess the degree to which regulation of the human globin genes mimic their normal pattern and levels of expression in the mouse model. We found that under these conditions the human genes are expressed in an appropriate developmental stage-and tissue-specific manner, although the level of expression of the a genes is only about 40% of that of the endogenous mouse a globin genes. This leads to abnormal red blood cells, and homozygotes for the human synteny replacement may die prematurely even though they are not frankly anemic. These differences between expression of the human gene in man and mouse could result from changes in the chromosomal environment, although the relationship between transcription and nuclear sublocalization remains unclear (Brown et al., 2006) . Perhaps more likely, changes in the structure or recognition sequences of the key transcription factors have altered during the evolution of the two species such that the binding or stability of mouse transcription factors on human sequences are suboptimal.
Knowing the phenotype resulting from expression of the normal human a globin cluster in mouse, it is now possible to compare and evaluate the effects of specific mutations introduced into the human sequence. Using RMGR, the only variable is the mutation itself. Such mutations could either be introduced by further rounds of homologous recombination in the humanized ES cells or, as demonstrated here, by recombineering the appropriate mutation into the modified BAC followed by a new round of RMGR at the target region. Again using the a globin cluster as the model we could show that removal of just 1.1 kb containing the major regulatory element (HS -40) virtually abolishes human a globin expression consistent with previous extensive observations (Higgs et al., 1998) . In homozygotes, this deletion mimics the lethal clinical phenotype of hydrops fetalis seen in human patients with this degree of a globin deficiency. We have previously shown that removal of the mouse sequence (HS -26), which is the equivalent of the human major regulatory element (HS -40), from the endogenous locus only reduces mouse a globin expression to $50% of normal, and homozygotes for this allele survive with only mild anemia rather than developing hydrops fetalis (Anguita et al., 2002) . This clearly shows that the detailed regulation of human and mouse genes may be quite different and emphasizes the point that extrapolating conclusions from studying regulation of an orthologous gene may be misleading when one wishes to determine how a particular human gene is regulated.
It seems likely that the observations set out here represent general recurrent issues that arise when making and analyzing mouse models of human gene regulation and genetic disease. RMGR will exclude most of the variables associated with current transgenic experiments, but it is still likely that human genes will not be completely faithfully regulated in mouse systems. However, comparing wildtype and mutant chromosomal domains iteratively inserted into an appropriate chromosomal environment will allow one to determine more precisely the effect of specific mutations. This will not only be of value when studying previously well-characterized loci but will also enable those studying complex traits to assess the functional role of mutations and SNPs localized within less well characterized large segments of the human genome.
EXPERIMENTAL PROCEDURES
ES Cell Gene Targeting Vectors
Replacement vectors were constructed in pBluescript (pBS) plasmid using 129/Ola strain cloned genomic DNA; (see Supplemental Data Section S1 for details). Vectors were linearized at a unique restriction site prior to electroporation.
BAC Retrofitting Vectors
Vectors were constructed in pBS plasmid using subcloned human BAC 344L6 DNA or duplex synthetic oligonucleotides, and selection cassettes with dual eukaryotic (PGK) and prokaryotic (Tn903 or EM7) promoters (Testa et al., 2003) ; (see Supplemental Data Section S2 for details). DNA restriction fragments used for electroporation were gel purified from the pBS backbone.
BAC Modifications
The BAC 344L6 was transferred into E. coli DY380 (gift from D. Court and N. Copeland) selected in chloramphenicol 12.5 mg/ml and electrocompetent cells then prepared for retrofitting (Lee et al., 2001) . l Redmediated recombination was carried out mixing 50 ml of cells with 150 ng to 300 ng purified DNA in a 0.1 cm wide cuvette using a Bio-Rad gene pulser set at 1.8 kV. Immediately after electroporation, 1 ml of SOC media was added, and the cells were further grown at 32 C for 2 hr before being plated on appropriate selective agar media. Drug concentrations: puromycin, 62.5 mg/ml; kanamycin, 12.5 mg/ml; blasticydin, 100 mg/ml; hygromycin, 50 mg/ml.
ES Cell Gene Targeting E14-TG2a.IV ES cells were grown as previously described (Nichols et al., 1990) . 75 mg of NotI linearized Dist targeting vector was electroporated into 5 3 10 7 E14-TG2a.IV cells as previously described (Smith et al., 2002) . Cells were selected in 160 mg/ml G418 and resistant colonies later picked into 96-well plates for freezing and DNA analysis. The Dist-targeted cell line was then used in a second round of electroporation to target the 3 0 q gene according to the procedure above.
Cells were selected in 1.5 mg/ml puromycin. Targeted clones were identified by Southern blot analysis of PstI-digested DNAs and hybridization with 5 0 and 3 0 external probes (5 0 , 0.22 kb XhoI/HindIII fragment; 3 0 , 0.45 kb BglII fragment).
Determination of in-cis Double Targeted Clones
Double-targeted ES cell clones were coelectroporated with 75 mg pBS vector containing a loxP/Hprt -D5 0 /lox511 cassette and 25 mg pCAGGSCre-IRESpuro plasmid (Smith et al., 2002) . 24 hr later, cells were plated at 5 3 10 6 cells per 10 cm dish. Cells were selected the following day in HAT supplemented medium (0.1 mM hypoxathine, 0.4 mM aminopterin, 0.016 mM thymidine). After 10 days, HAT R colonies were counted, picked into 96-well plates, and subsequently replica 96-well plates made for G418 and puromycin resistance/sensitivity testing. Details are provided in Supplemental Data Section S3.
BAC Exchange
Approximately 80 mg of retrofitted supercoiled BAC DNA (see Supplemental Data Section S4 for DNA preparation method) and 30 mg pCAGGS-Cre-IRESpuro plasmid DNA ($1:10 molar ratio) were mixed and coprecipitated with ethanol. The DNA pellet was dissolved in a final volume of 100 ml 90% phosphate-buffered saline (PBS), and the DNAs were very gently mixed with a 0.7 ml suspension of 5 3 10 7 to 1 3 10 8 double-targeted ES cells in PBS in a 0.4 cm wide Bio-Rad cuvette. Cells were electroporated at 0.25 kV, 960 mF using a Bio-Rad gene pulser and then plated into twenty 10 cm diameter dishes. 24 hr later, HAT supplemented media was added and left for 4 days. The medium was then changed to HT (0.1 mM hypoxanthine plus 0.016 mM thymidine) supplemented media, and any resistant colonies were picked 6-10 days later. The clones were subsequently expanded for freezing, DNA analysis, and testing resistance/sensitivity to the following: G418 (160 mg/ml), hygromycin (120 mg/ml), puromycin (1.5 mg/ml), blasticydin (5 mg/ml), ganciclovir (2.5 mM), 6-thioguanine (10 mM), HAT (0.1 mM hypoxathine, 0.4 mM aminopterin, 0.016 mM thymidine). DNA of potential replacement clones was first analyzed at the end points of the exchange event by SpeI digestion and hybridization with 5 0 and 3 0 mouse Dist probes and PstI digestion and hybridization with 5 0 and 3 0 mouse 3 0 q probes.
Hprt Cassette Deletion
Clones with a confirmed exchange event were electroporated with 75 mg supercoiled pCAGGS-FLPe-IRESpuro plasmid DNA (Schaft et al., 2001 ). The cells were grown nonselectively for 6 days and then plated out at 10 3 cells per 10 cm plate in medium with 10 mM 6-thioguanine. Resistant colonies were picked after 8 days into a 96-well plate for freezing and DNA analysis.
Generation of Chimeras and Breeding
All animal experiments were conducted under Home Office licenses after ethical review of the Universities of Edinburgh and Oxford. Chimeras were generated by injection of ES cells into C57/BL6 blastocysts and transfer into pseudopregnant recipients. Male chimeras were test-crossed with C57/BL6 mice. Agouti F1 test-cross offspring were genotyped by EcoRI digestion of tail biopsied DNA and hybridization with a human z gene probe. Test-cross positive heterozygotes were further backcrossed onto the C57BL/6 strain to maintain the lines. Test-cross positive heterozygotes were also bred with C57BL/ 6 3 CBA F1 mice, and heterozygotes on this mixed genetic background intercrossed to derive homozygotes. To derive lines with the Hprt cassette removed, F1 test-cross positive heterozygotes were crossed with a C57BL/6 FLPe germline deleter, and these were subsequently maintained by backcrossing with C57BL/6 mice and heterozygotes intercrossed to derive homozygotes.
DNA and RNA Analysis
Genomic DNA analysis and RNase protection assays were as previously described (Anguita et al., 2002) . DNA FISH studies were as described (Brown et al., 2006) . Total RNA was isolated from adult tissues or whole embryos using the Trizol reagent (Sigma) and analyzed by Affymetrix array as previously described (De Gobbi et al., 2006) and by quantitative real-time RT-PCR. Specific primers and TaqMan probes were designed with Primer Express software (ABI) and sequences used are provided in Table S2 .
Supplemental Data
The Supplemental Data for this article can be found online at http:// www.cell.com/cgi/content/full/128/1/197/DC1/. 
